Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Keros Therapeutics Inc (NASDAQ: KROS) was $11.13 for the day, down -2.37% from the previous closing price of $11.40. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 0.86 million shares were traded. KROS stock price reached its highest trading level at $11.35 during the session, while it also had its lowest trading level at $11.04.
Ratios:
Our analysis of KROS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On January 17, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $15.
Oppenheimer reiterated its Outperform rating for the stock on December 16, 2024, while the target price for the stock was revised from $102 to $63.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 450847360 and an Enterprise Value of -60550536. For the stock, the TTM Price-to-Sale (P/S) ratio is 693.60 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at -93.012 whereas that against EBITDA is 0.298.
Stock Price History:
The Beta on a monthly basis for KROS is 1.40, which has changed by -0.78190166 over the last 52 weeks, in comparison to a change of 0.21926713 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $9.77. The 50-Day Moving Average of the stock is -61.90%, while the 200-Day Moving Average is calculated to be -76.30%.
Shares Statistics:
KROS traded an average of 1.48M shares per day over the past three months and 1710760 shares per day over the past ten days. A total of 39.26M shares are outstanding, with a floating share count of 32.86M. Insiders hold about 18.87% of the company’s shares, while institutions hold 83.10% stake in the company. Shares short for KROS as of 1736899200 were 4017848 with a Short Ratio of 2.71, compared to 1734048000 on 3025140. Therefore, it implies a Short% of Shares Outstanding of 4017848 and a Short% of Float of 13.51.
